An observational study in Multiple Myeloma, sponsored by Bristol-Myers Squibb. Recruiting at 5 sites in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Bristol-Myers Squibb · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Multiple Myeloma by Bristol-Myers Squibb — 9 open to participants now, 18 under way, 6 of them phase 3. Multiple Myeloma · Bristol-Myers Squibb.
Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, this one is the 32nd largest by planned enrollment of the 35 observational ones that give a count, is one of 7 that started in 2024, is one of 35 observational ones, reaches primary completion later than 16 of the 17 other live ones, and was the 147th registered.
3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
Browse Multiple Myeloma studies →9 of the 149 studies in Multiple Myeloma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Celgene · Sites in United States, Canada, China and 5 more countries
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Canada and 1 more country
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Canada
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, France, Germany and 1 more country
Ages 18+
By country, each count listing its studies:
Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 38 · Phase 3 32
First in 2001; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 150 across 486 observational studies indexed under Multiple Myeloma.
Median enrollment 83 across the 108 interventional studies, 355 across the 35 observational. Of the 120 that completed or were terminated, 43 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
6 of the studies in Multiple Myeloma by Bristol-Myers Squibb that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05519085Phase 3CelgeneA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | 2027-01-10 |
| NCT04975997Phase 3CelgeneOpen-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | 2027-11-16 |
| NCT05688475Bristol-Myers SquibbA Rollover Study of CC-122 | 2026-11-30 |
| NCT03989414CelgeneA Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) | 2026-11-30 |
| NCT06988488CelgeneA Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma | 2027-05-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to monitor the long-term safety of participants who received idecabtagene vicleucel treatment as part of the KarMMa-9 (CA089-1043) Phase 3 clinical trial.
Adult participants with newly diagnosed multiple myeloma (NDMM) who had a suboptimal response after autologous stem cell transplantation (ASCT) and who were treated with idecabtagene vicleucel in the KarMMa-9 (CA089-1043) Phase 3 clinical trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Idecabtagene vicleucel
As per CA089-1043 study protocol
Participant adverse events
Time frame: Monthly from months 4-18, every 2 months from months 19-59, and annually from month year 5 to 15
Number of participants with positive replication-competent lentivirus test results
Time frame: At 4, 7, 13, and 25 months, and annually up to 15 years
Persistent vector sequence monitoring
Time frame: Months 7-18 and annually from years 5-15
Progression-free survival (PFS)
Time frame: Monthly up to 18 months and every two months after month 19 up to 15 years
Overall survival (OS)
Time frame: Every 3 months up to month 60, annually thereafter up to 15 years
Number of participants that achieve complete response or stringent complete response
Time frame: At months 4-18, every 2 months from months 19-59, and annually from years 5-15
Health-related quality of life (HRQoL) measured by the European Organization for Research and Treatment of Cancer core quality of life (EORTC QLQ-C30) questionnaire
Time frame: At months 4-18, every 2 months from months 19-59, and annually from years 5-15
Health-related quality of life (HRQoL) measured by the European Organization for Research and Treatment of Cancer assessment of quality of life of myeloma patients (EORTC QLQ-MY20) questionnaire
Time frame: At months 4-18, every 2 months from months 19-59, and annually from years 5-15
Health-related quality of life (HRQoL) measured by the EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire
Time frame: At months 4-18, every 2 months from months 19-59, and annually from years 5-15
Plan to share: No
Started Sep 2024 (actual). Primary completion is estimated for Mar 2031, 78 months after the start.
Of 66 industry-sponsored observational studies under Multiple Myeloma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 70. This study's planned 78 months is above that.
Counting every sponsor, half of 239 studies reached it within 57 months; a quarter within 30 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.